FFA3 Activation Stimulates Duodenal Bicarbonate Secretion and Prevents NSAID-Induced Enteropathy via the GLP-2 Pathway in Rats

Digestive Diseases and Sciences

Volumn 62, Issue 8, 2017, Pages 1944-1952

  Said, Hyder ^a   Akiba, Yasutada ^a,b,c   Narimatsu, Kazuyuki ^a   Maruta, Koji ^a   Kuri, Ayaka ^d   Iwamoto, Ken ichi ^d   Kuwahara, Atsukazu ^d   Kaunitz, Jonathan D ^a,b,c,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c Brentwood Biomedical Research Institute Los Angeles   (United States)

^d UNIVERSITY OF SHIZUOKA   (Japan)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Duodenal bicarbonate secretion; Free fatty acid receptors; Glucagon like peptide 2; NSAID induced enteropathy; Short chain fatty acid

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; AR 420626; BICARBONATE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR INHIBITOR; FATTY ACID RECEPTOR 3; GLUCAGON LIKE PEPTIDE 2; HORMONE RECEPTOR BLOCKING AGENT; INDOMETACIN; N (2 METHYLPHENYL) 4 [5 (2 TRIFLUOROMETHOXY PHENYL) FURAN 2 YL] 2 METHYL 5 OXO 1,4,5,6,7,8 HEXAHYDROQUINOLINE 3 CARBOXAMIDE; N [2 METHYLPHENYL] [4 FURAN 3 YL] 2 METHYL 5 OXO 1,4,5,6,7,8 HEXAHYDROQUINOLINE 3 CARBOXAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN INHIBITOR; RECEPTOR; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; CFTR PROTEIN, RAT; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FATTY ACID; FFAR3 PROTEIN, HUMAN; G PROTEIN COUPLED RECEPTOR; N-(2-METHYLPHENYL)-(4-FURAN-3-YL)-2-METHYL-5-OXO-1,4,5,6,7,8-HEXAHYDROQUINOLINE-3-CARBOXAMIDE; QUINOLONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DUODENUM; EC50; ENTEROPATHY; GASTROINTESTINAL TRACT; HEPATIC PORTAL VEIN; INTESTINE INJURY; INTESTINE ULCER; L CELL LINE; MALE; MYENTERIC PLEXUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; INTESTINAL DISEASES; INTESTINE MUCOSA; METABOLISM; SECRETION (PROCESS); SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; ULCER;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BICARBONATES; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DUODENUM; FATTY ACIDS, NONESTERIFIED; GLUCAGON-LIKE PEPTIDE 2; INDOMETHACIN; INTESTINAL DISEASES; INTESTINAL MUCOSA; MALE; QUINOLONES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; ULCER;

EID: 85019564044     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-017-4600-4     Document Type: Article

References (40)

1. Higuchi K, Umegaki E, Watanabe T, et al. Present status and strategy of NSAIDs-induced small bowel injury. J Gastroenterol. 2009;44:879–888.
2. Matsumoto T, Kudo T, Esaki M, et al. Prevalence of non-steroidal anti-inflammatory drug-induced enteropathy determined by double-balloon endoscopy: a Japanese multicenter study. Scand J Gastroenterol. 2008;43:490–496.
3. Graham DY, Opekun AR, Willingham FF, Qureshi WA. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol. 2005;3:55–59.
4. Wallace JL. NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategies. Br J Pharmacol. 2012;165:67–74.
5. Omatsu T, Naito Y, Handa O, et al. Reactive oxygen species-quenching and anti-apoptotic effect of polaprezinc on indomethacin-induced small intestinal epithelial cell injury. J Gastroenterol. 2010;45:692–702.
6. Duggan DE, Hooke KF, Noll RM, Kwan KC. Enterohepatic circulation of indomethacin and its role in intestinal irritation. Biochem Pharmacol. 1975;24:1749–1754.
7. Iwai T, Ichikawa T, Kida M, et al. Vulnerable sites and changes in mucin in the rat small intestine after non-steroidal anti-inflammatory drugs administration. Dig Dis Sci. 2010;55:3369–3376.
8. Shimizu K, Koga H, Iida M, Haruma K. Microcirculatory changes in experimental mesenteric longitudinal ulcers of the small intestine in rats. Dig Dis Sci. 2007;52:3019–3028.
9. Takeuchi K, Kita K, Hayashi S, Aihara E. Regulatory mechanism of duodenal bicarbonate secretion: roles of endogenous prostaglandins and nitric oxide. Pharmacol Ther. 2011;130:59–70.
10. Akiba Y, Guth PH, Engel E, Nastaskin I, Kaunitz JD. Dynamic regulation of mucus gel thickness in rat duodenum. Am J Physiol Gastrointest Liver Physiol. 2000;279:G437–G447.
11. Takeuchi K, Miyazawa T, Tanaka A, Kato S, Kunikata T. Pathogenic importance of intestinal hypermotility in NSAID-induced small intestinal damage in rats. Digestion. 2002;66:30–41.
12. Konaka A, Kato S, Tanaka A, Kunikata T, Korolkiewicz R, Takeuchi K. Roles of enterobacteria, nitric oxide and neutrophil in pathogenesis of indomethacin-induced small intestinal lesions in rats. Pharmacol Res. 1999;40:517–524.
13. Watanabe T, Higuchi K, Kobata A, et al. Non-steroidal anti-inflammatory drug-induced small intestinal damage is Toll-like receptor 4 dependent. Gut. 2008;57:181–187.
14. Wallace JL, Syer S, Denou E, et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology. 2011;141:1314–1322.
15. Uchida A, Yamada T, Hayakawa T, Hoshino M. Taurochenodeoxycholic acid ameliorates and ursodeoxycholic acid exacerbates small intestinal inflammation. Am J Physiol. 1997;272:G1249–G1257.
16. Inoue T, Higashiyama M, Kaji I, et al. Dipeptidyl peptidase IV inhibition prevents the formation and promotes the healing of indomethacin-induced intestinal ulcers in rats. Dig Dis Sci. 2014;59:1286–1295.
17. Guan X, Karpen HE, Stephens J, et al. GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow. Gastroenterology. 2006;130:150–164.
18. Wang JH, Inoue T, Higashiyama M, et al. Umami receptor activation increases duodenal bicarbonate secretion via glucagon-like peptide-2 release in rats. J Pharmacol Exp Ther. 2011;339:464–473.
19. Boushey RP, Yusta B, Drucker DJ. Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am J Physiol. 1999;277:E937–E947.
20. Rønnestad I, Akiba Y, Kaji I, Kaunitz JD. Duodenal luminal nutrient sensing. Curr Opin Pharmacol. 2014;19C:67–75.
21. Akiba Y, Inoue T, Kaji I, et al. Short-chain fatty acid sensing in rat duodenum. J Physiol. 2015;593:585–599.
22. 3− secretion. Am J Physiol. 1997;272:G872–G878.
23. Ulven T. Short-chain free fatty acid receptors FFA2/GPR43 and FFA3/GPR41 as new potential therapeutic targets. Front Endocrinol (Lausanne). 2012;3:111.
24. − secretion and duodenal ulcer formation in rats. Am J Physiol Gastrointest Liver Physiol. 2005;289:G753–G759.
25. Kaji I, Iwanaga T, Watanabe M, et al. SCFA transport in rat duodenum. Am J Physiol Gastrointest Liver Physiol. 2015;308:G188–G197.
26. 2 and pH regulation in rat duodenal mucosa. J Physiol. 2006;573:827–842.
27. Kaji I, Akiba Y, Konno K, et al. Neural FFA3 activation inversely regulates anion secretion evoked by nicotinic ACh receptor activation in rat proximal colon. J Physiol. 2016;594:3339–3352.
28. Kaji I, Akiba Y, Furuyama T, Kaunitz JD. FFA3 activation inhibits nicotine-induced secretion and motility via enteric nervous reflex in rat proximal colon. Gastroenterology. 2016;150:S352.
29. Inoue T, Wang JH, Higashiyama M, et al. Dipeptidyl peptidase IV inhibition potentiates amino acid- and bile acid-induced bicarbonate secretion in rat duodenum. Am J Physiol Gastrointest Liver Physiol. 2012;303:G810–G816.
30. Akiba Y, Kaunitz JD. Duodenal chemosensing and mucosal defenses. Digestion. 2011;83:25–31.
31. Hudson BD, Christiansen E, Murdoch H, et al. Complex pharmacology of novel allosteric free fatty acid 3 receptor ligands. Mol Pharmacol. 2014;86:200–210.
32. Brown AJ, Goldsworthy SM, Barnes AA, et al. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem. 2003;278:11312–11319.
33. Amelsberg M, Amelsberg A, Ainsworth MA, Hogan DL, Isenberg JI. Cyclic adenosine-3′,5′-monophosphate production is greater in rabbit duodenal crypt than in villus cells. Scand J Gastroenterol. 1996;31:233–239.
34. Ameen NA, Martensson B, Bourguinon L, Marino C, Isenberg J, McLaughlin GE. CFTR channel insertion to the apical surface in rat duodenal villus epithelial cells is upregulated by VIP in vivo. J Cell Sci. 1999;112:887–894.
35. Bahrami J, Yusta B, Drucker DJ. ErbB activity links the glucagon-like peptide-2 receptor to refeeding-induced adaptation in the murine small bowel. Gastroenterology. 2010;138:2447–2456.
36. Dong CX, Zhao W, Solomon C, et al. The intestinal epithelial insulin-like growth factor-1 receptor links glucagon-like peptide-2 action to gut barrier function. Endocrinology. 2014;155:370–379.
37. Nøhr MK, Egerod KL, Christiansen SH, et al. Expression of the short chain fatty acid receptor GPR41/FFAR3 in autonomic and somatic sensory ganglia. Neuroscience. 2015;290:126–137.
38. Akiba Y, Kaji I, Guth PH, Engel E, Kaunitz JD. GPR43 activation with COX inhibition induces duodenal injury via 5-HT pathway. Gastroenterology. 2014;146:S504–S505.
39. Fujiwara K, Inoue T, Yorifuji N, et al. Combined treatment with dipeptidyl peptidase 4 (DPP4) inhibitor sitagliptin and elemental diets reduced indomethacin-induced intestinal injury in rats via the increase of mucosal glucagon-like peptide-2 concentration. J Clin Biochem Nutr. 2015;56:155–162.
40. Sakanaka T, Inoue T, Yorifuji N, et al. The effects of a TGR5 agonist and a dipeptidyl peptidase IV inhibitor on dextran sulfate sodium-induced colitis in mice. J Gastroenterol Hepatol. 2015;30:60–65.